{"id":40849,"date":"2026-06-03T16:11:41","date_gmt":"2026-06-03T14:11:41","guid":{"rendered":"https:\/\/genomtec.com\/?p=40849"},"modified":"2026-06-08T16:11:53","modified_gmt":"2026-06-08T14:11:53","slug":"genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development","status":"publish","type":"post","link":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/","title":{"rendered":"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development"},"content":{"rendered":"<p><strong>Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million.<\/strong><\/p>\n<p><strong>The proceeds will support the commercialization and strategic partnering of Genomtec\u2019s proprietary diagnostic platforms, Genomtec ID\u00ae and OncoSNAAT\u00ae, while also accelerating the development of artificial intelligence tools designed to streamline molecular test development.<\/strong><\/p>\n<p><em>&#8220;We are pleased to have secured additional capital that enables us to execute the next phase of our commercialization strategy,&#8221;<\/em> <strong>said Miron Tokarski, CEO and co-founder of Genomtec<\/strong>. <em>&#8220;With funding secured, we can continue advancing strategic discussions around Genomtec ID and OncoSNAAT while investing in technologies that strengthen our competitive position, including AI-based solutions for molecular diagnostics development.&#8221;<\/em><\/p>\n<p>In parallel, Genomtec is executing a nearly EUR 1.65 million AI-focused project funded by the Lower Silesian Intermediate Body. The initiative applies artificial intelligence and machine learning to automate the design of LAMP-based primers, significantly reducing the time and cost required to develop new molecular diagnostic tests.<\/p>\n<p>The company will also continue advancing:<\/p>\n<p>The company will also continue advancing:<br \/>\n\u2022 Commercialization and strategic partnering activities for Genomtec ID\u00ae and OncoSNAAT\u00ae;<br \/>\n\u2022 Further optimization of the Genomtec ID\u00ae platform;<br \/>\n\u2022 Development of OncoSNAAT\u00ae, a liquid biopsy-based oncology diagnostics technology.<\/p>\n<p>Genomtec\u2019s flagship Genomtec ID\u00ae platform enables rapid molecular diagnostics at the point of care through a portable system combining proprietary SNAAT\u00ae technology with integrated testing capabilities. The company\u2019s OncoSNAAT\u00ae technology is being developed to support precision oncology through the detection of clinically relevant cancer-related genetic alterations.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million. The proceeds will support the commercialization and strategic partnering of Genomtec\u2019s proprietary diagnostic platforms, Genomtec ID\u00ae and OncoSNAAT\u00ae, while also accelerating the development of artificial [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":36430,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-40849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v18.4.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec\" \/>\n<meta property=\"og:description\" content=\"Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million. The proceeds will support the commercialization and strategic partnering of Genomtec\u2019s proprietary diagnostic platforms, Genomtec ID\u00ae and OncoSNAAT\u00ae, while also accelerating the development of artificial [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Genomtec\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T14:11:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T14:11:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1900\" \/>\n\t<meta property=\"og:image:height\" content=\"879\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin@genomtec.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genomtec.com\/#website\",\"url\":\"https:\/\/genomtec.com\/\",\"name\":\"Genomtec\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genomtec.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg\",\"contentUrl\":\"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg\",\"width\":1900,\"height\":879},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#webpage\",\"url\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/\",\"name\":\"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec\",\"isPartOf\":{\"@id\":\"https:\/\/genomtec.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#primaryimage\"},\"datePublished\":\"2026-06-03T14:11:41+00:00\",\"dateModified\":\"2026-06-08T14:11:53+00:00\",\"author\":{\"@id\":\"https:\/\/genomtec.com\/#\/schema\/person\/1a341d12370a22429e0515e03f637ecf\"},\"breadcrumb\":{\"@id\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/genomtec.com\/#\/schema\/person\/1a341d12370a22429e0515e03f637ecf\",\"name\":\"admin@genomtec.com\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/genomtec.com\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9e9cc6dab1109231f0b60cf5e90342d08d0039171ecbc1d500786ee9c62be7e7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9e9cc6dab1109231f0b60cf5e90342d08d0039171ecbc1d500786ee9c62be7e7?s=96&d=mm&r=g\",\"caption\":\"admin@genomtec.com\"},\"url\":\"https:\/\/genomtec.com\/en\/author\/admingenomtec-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/","og_locale":"en_US","og_type":"article","og_title":"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec","og_description":"Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million. The proceeds will support the commercialization and strategic partnering of Genomtec\u2019s proprietary diagnostic platforms, Genomtec ID\u00ae and OncoSNAAT\u00ae, while also accelerating the development of artificial [&hellip;]","og_url":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/","og_site_name":"Genomtec","article_published_time":"2026-06-03T14:11:41+00:00","article_modified_time":"2026-06-08T14:11:53+00:00","og_image":[{"width":1900,"height":879,"url":"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin@genomtec.com","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebSite","@id":"https:\/\/genomtec.com\/#website","url":"https:\/\/genomtec.com\/","name":"Genomtec","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genomtec.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#primaryimage","inLanguage":"en-US","url":"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg","contentUrl":"https:\/\/genomtec.com\/wp-content\/uploads\/2022\/05\/news_raport_q1_2022.jpg","width":1900,"height":879},{"@type":"WebPage","@id":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#webpage","url":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/","name":"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development - Genomtec","isPartOf":{"@id":"https:\/\/genomtec.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#primaryimage"},"datePublished":"2026-06-03T14:11:41+00:00","dateModified":"2026-06-08T14:11:53+00:00","author":{"@id":"https:\/\/genomtec.com\/#\/schema\/person\/1a341d12370a22429e0515e03f637ecf"},"breadcrumb":{"@id":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genomtec.com\/en\/2026\/06\/03\/genomtec-secures-over-eur-9-million-to-advance-commercialization-strategy-and-ai-powered-diagnostics-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development"}]},{"@type":"Person","@id":"https:\/\/genomtec.com\/#\/schema\/person\/1a341d12370a22429e0515e03f637ecf","name":"admin@genomtec.com","image":{"@type":"ImageObject","@id":"https:\/\/genomtec.com\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/9e9cc6dab1109231f0b60cf5e90342d08d0039171ecbc1d500786ee9c62be7e7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e9cc6dab1109231f0b60cf5e90342d08d0039171ecbc1d500786ee9c62be7e7?s=96&d=mm&r=g","caption":"admin@genomtec.com"},"url":"https:\/\/genomtec.com\/en\/author\/admingenomtec-com\/"}]}},"_links":{"self":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/posts\/40849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/comments?post=40849"}],"version-history":[{"count":1,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/posts\/40849\/revisions"}],"predecessor-version":[{"id":40850,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/posts\/40849\/revisions\/40850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/media\/36430"}],"wp:attachment":[{"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/media?parent=40849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/categories?post=40849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genomtec.com\/en\/wp-json\/wp\/v2\/tags?post=40849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}